MedTrace Logo

Role of Immune Responses After Acute Myocardial Infarction

NCT02428374 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2015-06-11

No results posted yet for this study

Summary

The fascinating role of lymphocyte subtypes in the development of coronary artery disease may be a new strategic target for understanding and therapy of acute myocardial infarction. The determinants of cell viability are unknown, postulating that they arise from factors not only related to microcirculation or energy expenditure, but also to inflammatory and immune responses. Furthermore, the intense mobilization of progenitor cells secondary to myocardial infarction triggers large lymphocyte proliferation that colonizes plaques in development, contributing to recurrent ischemic outcomes. This project aims to evaluate the immune and metabolic mechanisms involved in the recovery of the ischemic myocardium and coronary disease progression.

Conditions

  • Myocardial Fibrosis

Interventions

DRUG

Rosuvastatin plus clopidogrel

Crestor 40 mg daily plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo

DRUG

Rosuvastatin plus ticagrelor

Crestor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo

DRUG

Simvastatin plus clopidogrel

Zocor 40 mg plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo

DRUG

Simvastatin plus ticagrelor

Zocor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo

Sponsors & Collaborators

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

    collaborator OTHER_GOV

  • Federal University of São Paulo

    lead OTHER

Principal Investigators

  • Francisco A Fonseca, MD, PhD · Federal University of São Paulo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2018-04-30
Completion
2019-07-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02428374 on ClinicalTrials.gov